Efficacy of hepatitis B virus (HBV) vaccination in treating lamivudine‐resistant HBV reactivation following hepatitis B surface antigen seroconversion

Background: HBsAg vaccination might help to control HBV replication following nucleos(t)ide analog therapy. We tested HBsAg vaccine in a patient who developed lamivudine resistance.

[1]  S. Locarnini,et al.  Antiviral drug resistance: clinical consequences and molecular aspects. , 2006, Seminars in liver disease.

[2]  W. Yeo,et al.  Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy , 2006, Hepatology.

[3]  J. Marrero,et al.  Virologic response and resistance to adefovir in patients with chronic hepatitis B. , 2006, Journal of hepatology.

[4]  P. Colson,et al.  Unusual Selection of Rta181V Hbv Mutants Cross-Resistant to Adefovir following Prolonged Lamivudine Monotherapy: Report of Two Cases , 2005, Antiviral therapy.

[5]  M. Mancini-Bourgine,et al.  Therapeutic vaccination against chronic hepatitis B virus infection. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[6]  N. Nikolaidis,et al.  Interferon/long‐term lamivudine combination therapy in anti‐HBe positive chronic hepatitis B patients , 2005, Journal of gastroenterology and hepatology.

[7]  S. Fan,et al.  Failure of hepatitis B vaccination in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B. , 2005, Journal of hepatology.

[8]  Graeme Currie,et al.  Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. , 2005, The New England journal of medicine.

[9]  P. Colson,et al.  Fulminant hepatitis B associated with a specific insertion in the basal core promoter region of hepatitis B virus DNA after immunosuppressive treatment. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  R. Goldin,et al.  Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B. , 2005, Journal of hepatology.

[11]  Y. Hiasa,et al.  In vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach for treating patients with chronic hepatitis B. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[12]  A. Lok,et al.  Sustained response after a 2‐year course of lamivudine treatment of hepatitis B e antigen‐negative chronic hepatitis B , 2004, Journal of viral hepatitis.

[13]  William M. Lee,et al.  Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. , 2004, Gastroenterology.

[14]  R. Rubin,et al.  Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. , 2004, Gastroenterology.

[15]  C. Gibbs,et al.  Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. , 2003, Journal of hepatology.

[16]  A. Bertoletti,et al.  Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. , 2003, Journal of hepatology.

[17]  K. Yalçın,et al.  The Lack of Effect of Therapeutic Vaccination With a Pre-S2/S HBV Vaccine in the Immune Tolerant Phase of Chronic HBV Infection , 2003, Journal of clinical gastroenterology.

[18]  K. Yalçın,et al.  Specific Hepatitis B Vaccine Therapy in Inactive HBsAg Carriers: A Randomized Controlled Trial , 2003, Infection.

[19]  Angeline Bartholomeusz,et al.  Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. , 2003, Gastroenterology.

[20]  E. Schiff,et al.  Durability of serologic response after lamivudine treatment of chronic hepatitis B , 2003, Hepatology.

[21]  B. Dikici,et al.  Therapeutic vaccination in the immunotolerant phase of children with chronic hepatitis B infection , 2003, The Pediatric infectious disease journal.

[22]  M. Wulfsohn,et al.  Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. , 2003, The New England journal of medicine.

[23]  M. Wulfsohn,et al.  Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. , 2003, The New England journal of medicine.

[24]  E. Schiff,et al.  Histological outcome during long-term lamivudine therapy. , 2003, Gastroenterology.

[25]  M. Manns,et al.  Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the "fingers" subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene. , 2002, Virology.

[26]  D. Jackson,et al.  Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. , 2002, Virology.

[27]  C. Bréchot,et al.  Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. , 2001, Journal of hepatology.

[28]  J. Hoofnagle,et al.  Long‐term therapy of chronic hepatitis B with lamivudine , 2000, Hepatology.

[29]  S. Hadziyannis,et al.  Efficacy of long‐term lamivudine monotherapy in patients with hepatitis B e antigen–negative chronic hepatitis B , 2000, Hepatology.

[30]  Y. Liaw,et al.  Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. , 2000, Gastroenterology.

[31]  E. Schiff,et al.  Lamivudine as initial treatment for chronic hepatitis B in the United States. , 1999, The New England journal of medicine.

[32]  E. Schiff,et al.  Extended lamivudine retreatment for chronic hepatitis B: Maintenance of viral suppression after discontinuation of therapy , 1999, Hepatology.

[33]  C. Gibbs,et al.  Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro , 1998, Hepatology.

[34]  N. Leung,et al.  A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. , 1998, The New England journal of medicine.

[35]  A. Lok,et al.  Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. , 1991 .